Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) fell 3.9% during mid-day trading on Wednesday . The stock traded as low as $7.88 and last traded at $8.08. 657,495 shares traded hands during trading, an increase of 95% from the average session volume of 337,931 shares. The stock had previously closed at $8.41.
Silverback Therapeutics Trading Down 4.3 %
The firm has a 50-day moving average price of $8.88 and a 200-day moving average price of $7.73. The company has a market capitalization of $278.73 million, a price-to-earnings ratio of -3.19 and a beta of 0.60.
About Silverback Therapeutics
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
See Also
- Five stocks we like better than Silverback Therapeutics
- Financial Services Stocks Investing
- Dell and Super Micro Computer: Musk’s Favorite AI Hardware Stocks
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Top 3 Home Builder Stocks: Key Insights into the Housing Market
- What is a SEC Filing?
- Is Advanced Micro Devices Stock Ready for Another Run?
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
